Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma

  • Rita Pimenta Departamento de Dermatovenereologia, Centro Hospitalar Lisboa Norte, Hospital de Santa Maria, Lisboa, Portugal
  • Joaninha Costa-Rosa Departamento de Anatomia Patológica, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal
  • Mariana Cravo Departamento de Dermatologia, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal
  • Margarida Rafael Departamento de Dermatologia, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal
  • Cecília Moura Departamento de Dermatologia, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisboa, Portugal
Keywords: Melanoma, Drug-Related Side Effects and Adverse Reactions, Immunotherapy/adverse effects, Molecular Targeted Therapy, Skin/ drug effects


Targeted therapy and immunotherapy have markedly improved prognosis of advanced melanoma patients. With expanded use of these drugs, a range of cutaneous adverse events has emerged. Although the vast majority of adverse events are low-grade, they many cause significant morbidity and can affect patients' quality of life. Early diagnosis and prompt intervention may prevent unnecessary discontinuation of life-saving anticancer therapies. In this article, we review the cutaneous adverse events of small molecules and monoclonal antibodies used for the therapy of melanoma and discuss their pathophysiology and recommendations for prevention and management of these adverse events.


Download data is not yet available.


Jenkins RW, Fisher DE. Treatment of Advanced Melanoma in 2020 and Beyond. J Invest Dermatol. 2021;141:23-31. doi: 10.1016/j.jid.2020.03.943.

Keilholz U, Ascierto PA, Dummer R, Robert C, Lorigan P, van Akkooi A, et al. ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31:1435-48. doi: 10.1016/j.annonc.2020.07.004.

Michielin O, van Akkooi A, Lorigan P, Ascierto PA, Dummer R, Robert C, et al. ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee. Ann Oncol. 2020;31:1449-61. doi: 10.1016/j.annonc.2020.07.005.

Boada A, Carrera C, Segura S, Collgros H, Pasquali P, Bodet D, et al. Cutaneous toxicities of new treatments for melanoma. Clin Transl Oncol. 2018;20:1373-84. doi:10.1007/s12094-018-1891-7.

Hwang SJ, Anforth R, Carlos G, Fernandez-Peñas P. Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management. Actas Dermosifiliogr. 2017;108:6-16. doi:10.1016/

Gnanendran SS, Turner LM, Miller JA, Hwang SJE, Miller AC. Cutaneous Adverse Events of Anti-PD-1 Therapy and BRAF Inhibitors. Curr Treat Options Oncol. 2020;21:29. doi:10.1007/s11864-020-0721-7.

Ascierto PA, McArthur GA, Dréno B, Atkinson V, Liszkay G, Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol. 2016;17:1248-60. doi:10.1016/S1470-2045(16)30122-X.

Patel H, Yacoub N, Mishra R, White A, Long Y, Alanazi S, et al. Current Advances in the Treatment of BRAF-Mutant Melanoma. Cancers. 2020;12:482. doi:10.3390/cancers12020482.

Graf NP, Koelblinger P, Galliker N, Conrad S, Barysch M, Mangan J, et al. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma. J Eur Acad Dermatol Venereol. 2019;33:686-92. doi:10.1111/jdv.15363.

Anforth R, Carlos G, Clements A, Kefford R, Fernandez-Peñas P. Cutaneous adverse events in patients treated with BRAF inhibitor-based therapies for metastatic melanoma for longer than 52 weeks. Br J Dermatol. 2015;172:239-43. doi:10.1111/bjd.13200.

Lacouture M, Sibaud V. toxic side effects of targeted therapies and immunotherapies affecting the skin, oral mucosa, hair, and nails. Am J Clin Dermatol. 2018;19:31-9. doi:10.1007/s40257-018-0384-3.

Boull CL, Gardeen S, Abdali T, Li E, Potts J, Rubin N, et al. Cutaneous Reactions in Children Treated with MEK Inhibitors, BRAF Inhibitors, or Combination Therapy: A Multi-Center Study. J Am Acad Dermatol. 2020 (in press). doi:10.1016/j.jaad.2020.07.044.

Anforth R, Blumetti TC, Clements A, Kefford R, Long GV, Fernandez-Peñas P. Systemic retinoids for the chemoprevention of cutaneous squamous cell carcinoma and verrucal keratosis in a cohort of patients on BRAF inhibitors. Br J Dermatol. 2013;169:1310-3. doi: 10.1111/bjd.12519.

Chon SY, Sambrano BL, Geddes ER. Vemurafenib-related cutaneous side effects ameliorated by acitretin. J Drugs Dermatol. 2014;13:586-8.

Heinzerling L, Eigentler TK, Fluck M, Hassel JC, Heller-Schenck D, Leipe J, et al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 2019;4:e000491. doi:10.1136/esmoopen-2019-000491.

Zhao CY, Hwang SJE, Wakade D, Carlos G, Anforth R, Fernández-Peñas P. Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma: An observational study. Australas J Dermatol. 2017;58:292-8. doi:10.1111/ajd.12645.

Anforth RM, Carlos GR, Scolyer RA, Chou S, Fernandez-Peñas P. Eruptive naevi in a patient treated with LGX818 for BRAF mutant metastatic melanoma. Melanoma Res. 2015;25:91-4. doi:10.1097/CMR.0000000000000127.

Deutsch A, Balagula Y, McLellan BN. Anticancer therapies associated with secondary cutaneous malignancies: A review of the literature. J Am Acad Dermatol. 2020 (in press). doi:10.1016/j.jaad.2020.04.074.

Onnis G, Palmieri G, Montesu MA, Satta R. Second primary melanoma on a patient undergoing vemurafenib therapy. A case report. Int J Dermatol. 2017;56:792-4. doi:10.1111/ijd.13445.

Heppt MV, Clanner-Engelshofen BM, Marsela E, Wessely A, Kammerbauer C, Przybilla B, et al. Comparative analysis of the phototoxicity induced by BRAF inhibitors and alleviation through antioxidants. Photodermatol Photoimmunol Photomed. 2020;36:126-34. doi:10.1111/phpp.12520.

Eberlein B, Biedermann T, Hein R, Posch C. Vemurafenib-related photosensitivity. J Dtsch Dermatol Ges. 2020 (in press). doi:10.1111/ddg.14140.

Belum VR, Fischer A, Choi JN, Lacouture ME. Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep. 2013;15:249-59. doi:10.1007/s11912-013-0308-6.

Ferreira J, Toda-Brito H, Moura MC, Sachse MF, Costa-Rosa J. BRAFi-associated panniculitis - an emerging side effect with a variable histological picture: report of two cases and review of the literature. J Cutan Pathol. 2017;44:307-9. doi:10.1111/cup.12857.

Vance SL, Singer HM, Silvers D, Husain S, Kabigting F. Delayed-onset vemurafenib-induced panniculitis. JAAD Case Rep. 2017;3:384-6. doi:10.1016/j.jdcr.2017.06.001.

Richarz NA, Puig L, Pérez N, Cuadra-Urteaga J, Elez E, Fernández-Figueras MT. Vemurafenib-induced histiocytoid neutrophilic panniculitis simulating myeloid leukaemia cutis. Cancer Biol Ther. 2019;20:237-9. doi:10.1080/15384047.2018.1529113.

Hui Ong EL, Sinha R, Jmor S, Fearfield L. BRAF Inhibitor-Associated Granulomatous Dermatitis: A Report of 3 Cases. Am J Dermatopathol. 2019;41:214-7. doi:10.1097/DAD.0000000000001276.

Naqash AR, File DM, Ziemer CM, Whang YE, Landman P, Googe PB, et al. Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series. J Immunother Cancer. 2019;7:4. doi:10.1186/s40425-018-0475-y.

Anforth R, Liu M, Nguyen B, Uribe P, Kefford R, Clements A, et al. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib. Australas J Dermatol. 2014;55:250-4. doi:10.1111/ajd.12124.

Habre M, Salloum A, Habre SB, Abi Chebl J, Dib R, Kourie HR. Skin adverse events in recently approved targeted therapies in solid malignancies. Future Oncol. 2019;15:331-43. doi:10.2217/fon-2018-0402.

Abdel-Rahman O, ElHalawani H, Ahmed H. Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis. Future Oncol. 2015;11:3307-19. doi:10.2217/fon.15.265.

Wang CJ, Brownell I. BRAF Inhibitors for the Treatment of Papulopustular Eruptions from MAPK Pathway Inhibitors. Am J Clin Dermatol. 2020 (in press). doi:10.1007/s40257-020-00539-7.

Satoh TK, Mellett M, Meier-Schiesser B, Fenini G, Otsuka A, Beer HD, et al. IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes. J Clin Invest. 2020;130:1417-30. doi:10.1172/JCI128678.

Robert C, Sibaud V, Mateus C, Verschoore M, Charles C, Lanoy E, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16:e181-9. doi:10.1016/S1470-2045(14)71133-7.

Plachouri KM, Georgiou S. Therapeutic approaches to pyogenic granuloma: an updated review. Int J Dermatol. 2019;58:642-8. doi:10.1111/ijd.14268.

Peng L, Wang Y, Hong Y, Ye X, Shi P, Zhang J, et al. Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis. Oncotarget. 2017;8:83280-91. doi:10.18632/oncotarget.21059.

Pires E, Moura C. Immune Response in Melanoma: A Basis to Understand the Role of Immunotherapy with Immune Checkpoint Inhibitors. J Port Soc Dermatol Venereol. 2018;76:47-52. doi:10.29021/spdv.76.1.868

Pires E, Moura C. Immune Checkpoint Inhibitors in Melanoma: Review and Update.. J Port Soc Dermatol Venereol. 2018;76:237-52. doi:10.29021/spdv.76.3.970

Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DY, Moy AP, et al. CME Part II: Immune checkpoint inhibitor-related dermatologic adverse. J Am Acad Dermatol. 2020 (in press). doi:10.1016/j.jaad.2020.03.132.

Muntyanu A, Netchiporouk E, Gerstein W, Gniadecki R, Litvinov IV. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [published online ahead of print, 2020 Aug 3]. J Cutan Med Surg. doi:10.1177/1203475420943260.

Lu J, Thuraisingam T, Chergui M, Nguyen K. Nivolumab-associated DRESS syndrome: A case report. JAAD Case Rep. 2019;5(3):216-218. doi:10.1016/j.jdcr.2018.11.017.

Mirza S, Hill E, Ludlow SP, Nanjappa S. Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome. Melanoma Res. 2017;27:271-3. doi:10.1097/CMR.0000000000000326.

Logan IT, Zaman S, Hussein L, Perrett CM. Combination Therapy of Ipilimumab and Nivolumab-associated Toxic Epidermal Necrolysis (TEN) in a Patient With Metastatic Melanoma: A Case Report and Literature Review. J Immunother. 2020;43:89-92. doi:10.1097/CJI.0000000000000302.

Cohen BE, Manga P, Lin K, Elbuluk N. Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences . Am J Clin Dermatol. 2020 (in press).doi:10.1007/s40257-020-00524-0.

Ramondetta A, Ribero S, Conti L, Fava P, Marra E, Broganelli P, et al. Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors. Acta Derm Venereol. 2020;100:adv00001. doi:10.2340/00015555-3319.

Curry JL, Reuben A, Szczepaniak-Sloane R, Ning J, Milton DR, Lee CH, et al. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14+ and CD16+ monocytes driving an innate immune response. J Cutan Pathol. 2019;46:627-36. doi: 10.1111/cup.13454.

Dimitriou F, Frauchiger AL, Urosevic-Maiwald M, Naegeli MC, Goldinger MS, Barysch M, et al. Sarcoid-like reactions in patients receiving modern melanoma treatment. Melanoma Res. 2018;28:230-6. doi:10.1097/CMR.0000000000000437.

Hwang SJE, Park JJW, Wakade D, Chou S, Byth K, Fernandez-Penas P. Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma. Melanoma Res. 2019;29:172-7. doi:10.1097/CMR.0000000000000518.

McArthur GA, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S et al. CT012 e Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients with BRAFV600 mutation-positive advanced melanoma: primary results from the phase 3 IMspire150

trial. AACR Virtual. Annual Meeting. April 27e28, 2020.

How to Cite
Pimenta, R., Costa-Rosa, J., Cravo, M., Rafael, M., & Moura, C. (2021). Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma. Journal of the Portuguese Society of Dermatology and Venereology, 79(1), 11-20.
Continuous Medica Education

Most read articles by the same author(s)